[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:soluble-epidermal-growth-factor-receptor":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","Soluble Epidermal Growth Factor Receptor",18,[8,16,22,28,34,41,47,53,60,66,72,78,84,90,96,102,108,114],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07612189","A Phase 1 Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:18:42.501841Z","2026-05-29T15:36:40.230911Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06736379","Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer",[12],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:28.548931Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06415487","ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)",[12],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:28.536177Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT04412616","ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies",[12],"2026-08-26T02:18:47.742071Z","2026-05-05T02:35:31.759925Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":39,"content_modified":40},"NCT06616766","A Phase 1\u002F2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946",[38],"Phase 1\u002FPhase 2","2026-08-26T02:18:15.214990Z","2026-05-05T02:35:31.680026Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT04665206","Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors",[38],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:29.217787Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT05315700","Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration",[38],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.704037Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT03175224","APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors",[57],"Phase 2","2026-08-26T02:18:02.701182Z","2026-05-05T02:43:28.208686Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06804824","A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.192980Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06618287","A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors",[38],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:27.174109Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05579366","Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01\u002F PRO1184-001)",[38],"2026-08-26T02:17:02.694423Z","2026-07-05T05:32:16.807199Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05076760","MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",[12],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:28.200826Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT04429542","Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.748848Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06960395","Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",[12],"2026-08-26T02:15:41.377360Z","2026-05-05T02:43:27.743517Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06682793","A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression",[38],"2026-08-26T02:14:59.425132Z","2026-05-05T02:43:26.900916Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05269381","Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors",[38],"2026-08-26T02:19:10.436356Z","2026-04-29T02:57:57.121665Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07085091","A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors",[12],"2026-08-26T02:17:26.640202Z","2026-04-29T02:57:57.063184Z",{"nct_id":115,"title":116,"phases":117,"status":118,"updated_at":119,"content_modified":120},"NCT06507306","A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:23:21.062956Z","2026-04-29T02:57:57.103001Z"]